PTC Therapeutics Price To Sales vs. Shares Outstanding
PTCT Stock | USD 49.67 0.32 0.64% |
PTC Therapeutics Price To Sales Ratio |
|
For PTC Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of PTC Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well PTC Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between PTC Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of PTC Therapeutics over time as well as its relative position and ranking within its peers.
PTC |
PTC Therapeutics' Revenue Breakdown by Earning Segment
Check out Your Equity Center.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PTC Therapeutics. If investors know PTC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PTC Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.94) | Revenue Per Share 11.787 | Quarterly Revenue Growth 0.001 | Return On Assets (0.05) | Return On Equity (77.40) |
The market value of PTC Therapeutics is measured differently than its book value, which is the value of PTC that is recorded on the company's balance sheet. Investors also form their own opinion of PTC Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is PTC Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PTC Therapeutics' market value can be influenced by many factors that don't directly affect PTC Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PTC Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if PTC Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PTC Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
PTC Therapeutics Shares Outstanding vs. Price To Sales Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining PTC Therapeutics's current stock value. Our valuation model uses many indicators to compare PTC Therapeutics value to that of its competitors to determine the firm's financial worth. PTC Therapeutics is rated below average in price to sales category among its peers. It is regarded fourth in shares outstanding category among its peers creating about 18,016,937 of Shares Outstanding per Price To Sales. At this time, PTC Therapeutics' Price To Sales Ratio is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value PTC Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.PTC Shares Outstanding vs. Price To Sales
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
PTC Therapeutics |
| = | 4.28 X |
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
PTC Therapeutics |
| = | 77.13 M |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
PTC Shares Outstanding Comparison
PTC Therapeutics is currently under evaluation in shares outstanding category among its peers.
PTC Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in PTC Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, PTC Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of PTC Therapeutics' change in net profit over the period of time. It can combine multiple indicators of PTC Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last Reported | Projected for Next Year | ||
Accumulated Other Comprehensive Income | -1.3 M | -1.3 M | |
Operating Income | -349.4 M | -331.9 M | |
Income Before Tax | -696.1 M | -661.3 M | |
Total Other Income Expense Net | -346.7 M | -329.4 M | |
Net Loss | -503.1 M | -478 M | |
Net Loss | -626.6 M | -595.3 M | |
Income Tax Expense | -69.5 M | -66 M | |
Net Loss | -641.7 M | -609.6 M | |
Non Operating Income Net Other | -44.3 M | -42.1 M | |
Interest Income | 14.4 M | 10.5 M | |
Net Interest Income | -109.4 M | -103.9 M | |
Change To Netincome | 130.8 M | 79 M | |
Net Loss | (8.37) | (8.79) | |
Income Quality | 0.25 | 0.24 | |
Net Income Per E B T | 0.90 | 1.11 |
PTC Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on PTC Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of PTC Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the PTC Therapeutics' important profitability drivers and their relationship over time.
Use PTC Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if PTC Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in PTC Therapeutics will appreciate offsetting losses from the drop in the long position's value.PTC Therapeutics Pair Trading
PTC Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to PTC Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace PTC Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back PTC Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling PTC Therapeutics to buy it.
The correlation of PTC Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as PTC Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if PTC Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for PTC Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your PTC Therapeutics position
In addition to having PTC Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Sovereign ETFs Thematic Idea Now
Sovereign ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Sovereign ETFs theme has 17 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Sovereign ETFs Theme or any other thematic opportunities.
View All Next | Launch |
Additional Tools for PTC Stock Analysis
When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.